Evaluating oral EGCG for treating low-grade cervical lesions linked to HPV
Evaluation of Oral Epigallocatechin Gallate Treatment for Low-grade Cervical Lesions (L-SIL) Associated With Human Papilloma Virus (HPV) Infection
This study is testing if a natural compound called EGCG can help women with low-grade cervical lesions caused by HPV get better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | University of Palermo Academic / other |
| Locations | 1 site (Palermo) |
| Trial ID | NCT06314113 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of oral Epigallocatechin Gallate (EGCG) in treating Low-Grade Intraepithelial Neoplasia (L-SIL) associated with Human Papilloma Virus (HPV) infection. HPV is a common sexually transmitted infection that can lead to various cervical lesions, and while many infections resolve spontaneously, some can persist and cause complications. The study aims to determine if EGCG can enhance the resolution of these lesions. It involves women diagnosed with L-SIL and excludes those with certain health conditions or higher-grade lesions.
Who should consider this trial
Good fit: Ideal candidates are women diagnosed with Low-Grade Intraepithelial Neoplasia (L-SIL) associated with HPV infection.
Not a fit: Patients who are pregnant, have immunosuppressive conditions, or have a history of higher-grade cervical lesions will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for women with low-grade cervical lesions, potentially reducing the need for more invasive procedures.
How similar studies have performed: While the use of EGCG in this context is novel, other studies have explored its potential benefits in various cancer-related conditions, showing promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection Exclusion Criteria: * Pregnancy * Concomitant pathologies causing immunosuppression * Concurrent Immunomodulatory therapies * Hormone replacement therapy * High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma * Previous history of L-SIL or higher grade lesions ≥ 24 months
Where this trial is running
Palermo
- "Paolo Giaccone" Hospital — Palermo, Italy (Recruiting)
Study contacts
- Principal investigator: Antonio Simone Laganà, M.D., Ph.D. — University of Palermo
- Study coordinator: Antonio Simone Laganà, M.D., Ph.D.
- Email: antoniosimone.lagana@unipa.it
- Phone: +39 3296279579
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.